Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_3
4
100%

Phase Distribution

0

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
4(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Active, not recruiting2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 34 (100.0%)

Trials by Status

active_not_recruiting250%
completed250%

Recent Activity

2 active trials
Showing 4 of 4
active_not_recruitingphase_3

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

NCT05505916
completedphase_3

Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

NCT06467084
active_not_recruitingphase_3

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

NCT05511922
completedphase_3

A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

NCT05259917

Clinical Trials (4)

Showing 4 of 4 trials
NCT05505916Phase 3

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Active Not Recruiting
NCT06467084Phase 3

Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

Completed
NCT05511922Phase 3

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Active Not Recruiting
NCT05259917Phase 3

A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4